Creo Medical Group PLC Exercise of Options (6769N)
May 10 2018 - 6:25AM
UK Regulatory
TIDMCREO
RNS Number : 6769N
Creo Medical Group PLC
10 May 2018
Creo Medical Group plc
Exercise of Options
Chepstow, Wales - 10 May 2018 - Creo Medical Group plc (AIM:
CREO) ("Creo" or the "Company"), a medical device company focused
on the emerging field of surgical endoscopy, confirms that it has
issued, conditional on admission, 20,000 new ordinary shares of
GBP0.001 each in the capital of Creo (the "New Shares"), pursuant
to an exercise of share options.
Application has been made to the London Stock Exchange for
admission of the New Shares to trading on AIM and dealings are
expected to commence on 17 May 2018 ("Admission"). Following
Admission, Creo will have a total of 81,123,065 ordinary shares of
GBP0.001 each in issue. This figure may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in Creo.
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Brett Pollard / Mo
+44 (0)129 160 6005 Connelly (NOMAD) Noonan
Michael Johnson / +44 (0)203 727 1000
Russell Kerr (Sales) creo@fticonsulting.com
+44 (0)207 397 8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing safer, less-invasive and more cost-efficient
option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEMMGMKGGNGRZM
(END) Dow Jones Newswires
May 10, 2018 06:25 ET (10:25 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024